05
Mar

Merck and its biotech partner are working to build a franchise of allergy immunotherapies, and their latest effort, an oral treatment for house dust mite reactions, improved symptoms in a mid-stage study.

…read more

Source: Merck’s latest allergy pill hits the mark in Phase IIb

    

0 No comments